US FDA grants full approval to Moderna's vaccine against Covid-19

Moderna's Covid-19 vaccine has been available under the FDA's emergency use authorization for individuals 18 years of age and older since December 18, 2020

Moderna Covid-19 vaccine
IANS Washington
1 min read Last Updated : Feb 01 2022 | 8:58 AM IST

Moderna's Covid-19 vaccine has received full approval from the US Food and Drug Administration (FDA).

The vaccine, named Spikevax, is approved for use in people ages 18 and older, Xinhua news agency reported.

Spikevax meets the FDA's rigorous standards for safety, effectiveness and manufacturing quality required for approval, said the agency in a statement.

"While millions of people have already safely received Covid-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," said Acting FDA Commissioner Janet Woodcock.

"Today's milestone puts us one step closer to altering the course of this pandemic in the US," she said.

Moderna's Covid-19 vaccine is the second one in the US to receive full approval from the FDA. Pfizer's Covid-19 vaccine, Comirnaty, was fully approved for use in people ages 16 and older in August 2021.

Moderna's Covid-19 vaccine has been available under the FDA's emergency use authorization for individuals 18 years of age and older since December 18, 2020.

--IANS

int/shs

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Feb 01 2022 | 8:58 AM IST

Next Story